CSCarlos A. Q. Santos

Carlos A. Q. Santos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Carlos A. Q. Santos has a total of 210 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Allograft Rejection and the Latent HIV Reservoir in Kidney Transplant Recipients With HIV

    by Andrew Sulaiman, Miruthula Tamil Selvan, Ping Yang, Xianming Zhu, Yolanda Eby, Sarah E Benner, Reinaldo E Fernandez, Sarah Hussain, Diane Brown, Niraj Desai, et al.

    People with HIV-1 have higher risk for rejection after kidney transplantation but the mechanism is poorly understood. As HIV latency promotes immune dysregulation and chronic inflammation, we evaluated whether the size of the HIV latent viral reservoir (LVR) at baseline and through 52-weeks is associated with rejection in kidney transplant recipients with HIV from donors with and without HIV. Using the intact proviral DNA assay, we found no differences in the LVR between those who experienced rejection (n = 14) versus those who did not (N = 55) regardless of donor HIV status. These data support the feasibility of HIV+ to HIV+ organ transplantation. Clinical Trials Registration. NCT03500315.


  • Open Access

    Human antibody repertoire among kidney donors with and without HIV

    by Xianming Zhu, William R. Morgenlander, Diane M. Brown, Yolanda Eby, Megan Morsheimer, Jonah Odim, Serena M. Bagnasco, Meenakshi M. Rana, Sander S. Florman, Rachel J. Friedman-Moraco, et al.

    BACKGROUND: Transplanting kidneys from donors with HIV to recipients with HIV has become standard clinical practice. However, donors with HIV may have higher prevalence of viral and bacterial infections and autoimmunity that could increase allograft rejection in recipients. METHODS: We included deceased kidney donors (60 with HIV and 41 without HIV) who participated in a multicenter prospective study of HIV kidney transplantation between April 2018 and September 2021. Using phage immunoprecipitation sequencing, we compared the human antibody repertoire (allergens, autoantibodies, viruses, and bacterial toxins) between donors with and without HIV and evaluated their association with recipient allograft rejection. Moderated t tests were used to assess reactivity and a multivariate logistic regression model adjusted for donor sex and kidney donor profile index assessed the association between donor adenovirus reactivity and recipient allograft rejection. RESULTS: Compared with donors without HIV, donors with HIV had lower BMI and were more likely to be African American. The median number of positive autoantibodies was marginally higher among donors with HIV (499 [IQR, 357, 579]) compared with that of donors without HIV (395 [IQR, 256, 538], P = 0.058). Donors with HIV additionally had significantly higher antibody reactivity to Epstein-Barr virus and cytomegalovirus ( q < 0.05). Among all donors with and without HIV, antibodies against adenovirus were significantly associated with increased rejection among recipients, including after adjusting for false discovery ( q < 0.05) and also adjusting for demographic factors using multivariable logistic regression (odds ratio = 4.97; 95% CI = 1.89–13.61). CONCLUSION: The presence of antibodies against adenovirus infection in kidney donors with HIV may be associated with allograft rejection. TRIAL REGISTRATION: ClinicalTrials.gov NCT03500315. FUNDING: US NIH.

  • Infections After Kidney Transplantation From Donors With HIV to Recipients With HIV

    by Elizabeth C Arant, Thibaut Davy-Mendez, Tao Liang, Moreno Rodrigues, Cynthia L Gay, Meenakshi M Rana, Rachel Friedman-Moraco, Alexander Gilbert, Peter Stock, Sapna A Mehta, et al.

    Background: Kidney transplantation (KT) from donors with human immunodeficiency virus (HIV-1) to recipients with HIV (HIV D+/R+) is noninferior to KT from donors without HIV (HIV D−/R+) with regard to safety. However, there may be differences in posttransplant infections. Methods: We performed a secondary analysis of the HOPE in Action KT Study (NCT02602262) comparing the time to first clinically relevant infection within 24 months posttransplantation in 99 HIV D+/R+ versus 99 HIV D−/R+. Secondary outcomes included incidence rates, infection-related death, and timing of clinically relevant infection, each stratified by donor HIV status. Results: The cumulative incidence of a clinically relevant infection at 24 months posttransplantation was 73.8% (95% confidence interval [CI]: 63.1%–81.2%) for HIV D+/R+ versus 64.7% (95% CI: 53.0%–73.4%) for HIV D−/R+. Comparing time to first clinically relevant infection in HIV D+/R+ versus HIV D−/R+, the adjusted hazard ratio (aHR) was 1.44 (95% CI: 1.01–2.04) at 24 months posttransplantation; for infections associated with hospitalization, the aHR was not significantly higher (1.21 [95% CI: .78–1.86). There were no significant differences in the number of infections, death from infection, duration, or site of infection between HIV D+/R+ versus HIV D−/R+, though viral infections were numerically more common in HIV D+/R+ (40% vs 35%). Conclusions: Although there was a statistically significant association between receipt of a kidney from a donor with HIV and time to first clinically relevant infection in the 24 months posttransplantation, there were no differences in infections associated with hospitalization. These data are overall reassuring as this emerging practice expands into clinical care. Clinical Trials Registration. NCT02602262.

  • Open Access

    Bruton tyrosine kinase inhibitors and invasive aspergillosis and mucormycosis: a case report and multi-center exploratory retrospective study

    by Eric Bhaimia, Daniel Russell, Carlos A. Q. Santos

    Background: Bruton tyrosine kinase inhibitors (BTKIs) are increasingly utilized for patients with certain malignant hematologic conditions. While cases of invasive fungal infections have been reported in patients on BTKIs, no multi-center epidemiological studies have been performed. The Epic Cosmos platform, a nationwide electronic health record data set, provides an opportunity to assess real-world epidemiologic data. Case Summary: A 69-year-old female with recently diagnosed Waldenström macroglobulinemia with associated autoimmune hemolytic anemia undergoing treatment with zanubrutinib and prednisone presented with fatigue and acute kidney injury. Imaging demonstrated a bladder mass with bilateral hydronephrosis leading to transurethral resection of the bladder mass with histopathology revealing both broad ribbon-like hyphae resembling Mucorales spp. and acute-angle branching resembling Aspergillus spp. with angioinvasion. Additional imaging revealed bilateral pulmonary cavitary lesions and renal and brain involvement. Bronchoalveolar lavage returned a positive galactomannan and culture growth of Aspergillus fumigatus . The patient was treated with liposomal amphotericin B with eventual transition to oral isavuconazole. Zanubrutinib and steroids were discontinued. To assess real-world occurrence of IFIs in patients on BTKIs, we performed an exploratory analysis using Epic Cosmos. Conclusion: IFIs continue to be described in patients undergoing treatment with BTKIs. Through exploratory analysis using Epic Cosmos, aspergillosis occurred not infrequently (0.5%–1.9%) in patients on various BTKIs. Of patients on ibrutinib with a diagnosis of chronic graft-versus-host disease, aspergillosis was identified in 32 (8.3%) patients. Patients on BTKIs who developed aspergillosis were frequently on corticosteroids. Mucormycosis in patients on BTKIs was rare (<0.1%).


  • Using Encounter-Level Data for Risk-Adjustment of Antimicrobial Use Comparisons: Feasibility and Variable Selection

    by Rebekah W Moehring, Michael E Yarrington, Elizabeth Dodds Ashley, Rachel M Addison, Whitney R Buckel, Sara E Cosgrove, Danielle Doughman, Eili Klein, Carlos A Q Santos, Emily S Spivak, et al.

    Background: External comparisons of hospital antimicrobial use (AU), risk-adjusted using encounter characteristics, may better inform antimicrobial stewardship program strategy. Barriers to encounter-level modeling include feasibility of data collection and defining optimal methods for selecting input variables for risk-adjustment purposes. Methods: We measured achievements in sharing validated, encounter-level AU data among a multisystem hospital collaborative. Then, we performed retrospective analyses to compare variable selection strategies for AU risk-adjustment models. Electronic health record data from 50 US hospitals from 2020 to 2021 were split for model training and testing. Four input variable strategies were compared: (1) diagnosis-related group categories, (2) adjudicated Elixhauser comorbidity categories, (3) agnostic strategy including all diagnosis and procedure categories from AHRQ's Clinical Classification Software Refined (CCSR), and (4) adjudicated strategy where CCSR categories not appropriate for risk-adjustment were excluded by expert consensus. Gradient-boosted machine tree-based models estimated antibacterial days of therapy (DOT). Accuracy was measured for each strategy using mean absolute error (MAE); correlation plots compared model estimates and observed DOT among testing encounters. The top 20 most influential variables were defined using model variable importance. Results: Fifty of 76 hospitals successfully shared validated datasets using local resources. MAE was lowest for modeling strategies with larger numbers of CCSR inputs. Agnostic and adjudicated strategies had highly correlated estimates and similar influential variables. Conclusions: Expert adjudication required personnel effort and potentially introduced biases, yet did not produce results different from an agnostic approach. Risk-adjustment incorporating large encounter-level data and machine learning may prove feasible and meaningful in future hospital AU assessments.


  • Open Access

    Neighborhood sociome factors and pediatric asthma exacerbations: Protective role of tree crown density and importance of pharmacy access in Chicago's south side

    by Sandra Tilmon, Shashi Bellam, Kathy Bobay, Ellen Cohen, Emily Dillon, Brian Furner, Sarah E. Gray, Julie Johnson, David Meltzer, Doriane Miller, et al.

    Background: Pediatric asthma exacerbations remain a critical public health concern, particularly in historically underserved urban settings. Objective: This study investigates sociome factors—the social context of disease—associated with asthma exacerbations among children living in Chicago's South Side, leveraging clinical and publicly available generalizable census tract‐level datasets from agencies including ChiVes, the City of Chicago Data Portal, EPA, Census Bureau, HUD, NOAA, and more. The aim is to uncover novel hypotheses for potential new interventions. Methods: A generalized linear model assessed associations with the outcome of asthma exacerbations while accounting for clustering at the patient level. Predictors included all variables from the Sociome Data Commons, including social, environmental, behavioral, economic, housing, and school variables. Results: Predictors of decreased risk included patient age (+4.8 years, −22%), tree crown density (+6% coverage, −17%), parks per acre (+0.41, −8%), and labor market engagement (+0.8 points, −9%). Conversely, predictors of increased risk included increased distance to the nearest pharmacy (+0.28 miles, +12%), limited English skills (+2.3%, +10%), higher inequality (+0.08 points, +8%), and visits in the Spring (+11%) and Fall (+20%). Conclusion: The results suggest that tree crown density, a novel finding in the context of asthma exacerbations, may play a protective role. Limited access to health care facilities such as pharmacies continues to complicate care. Clinical Implications: These findings provide hypotheses for future interventions for long‐standing asthma disparities.


  • HIV Superinfection in Kidney Transplant Recipients With HIV Who Received Organs From Donors With HIV

    by Gracie M Rozek, Ping Yang, Yolanda Eby, Sarah E Benner, Craig Martens, Feben Habtehyimer, Maggie Chahoud, Diane Brown, Niraj M Desai, Sander Florman, et al.

    Transplantation of kidneys from donors with HIV to recipients with HIV (HIV D+/R+) has been shown to be safe and effective, but there is a unique risk of donor-derived HIV superinfection (HIV-SI) in these recipients. Recipients from a multicenter observational HIV D+/R+ study were examined for HIV-SI by site-directed next-generation sequencing (Illumina). Eighteen recipients of HIV D+/R+ kidney transplants had baseline and follow-up samples that successfully amplified. One recipient was confirmed to have experienced donor-derived HIV-SI at week 26 but did not experience any clinically significant changes. HIV-SI in recipients of HIV D+/R+ transplants is rare, and the clinical ramifications appear negligible.


  • Kaposi Sarcoma–Associated Herpesvirus Risk and Disease in Kidney Donors and Transplant Recipients With Human Immunodeficiency Virus in the United States

    by Puja H Nambiar, Tao Liang, Nazzarena Labo, Jonathan Hand, Emily A Blumberg, Meenakshi M Rana, Sander Florman, Brandy Haydel, Michele I Morris, Joanna Schaenman, et al.

    Background: Due to high prevalence of Kaposi sarcoma–associated herpesvirus (KSHV) among people with human immunodeficiency virus (HIV), KSHV-associated disease (KAD) may be increased after kidney transplantation from donors with HIV (HIV D+) to recipients with HIV (HIV R+). Methods: Anti-KSHV antibodies were measured in HIV R+ and donors with and without HIV (HIV D–) using a 30-antigen multiplex assay within 3 multicenter kidney transplantation studies. KSHV seropositivity was defined as reactivity to conventional KSHV antigens (≥1 ORF73 or K8.1); reactivity to expanded 5-antigen and 30-antigen panels were also reported. Risk factors were identified using modified Poisson regression. Recipients were monitored for posttransplant anti-KSHV antibody changes and KAD. Results: KSHV seroprevalence was 40.6% (143/352) among HIV R+, 25.2% (33/131) among HIV D+, and 7.5% (4/53) among HIV D–. In the multivariable model, only men who have sex with men (MSM) status was associated with KSHV seropositivity (relative risk, 1.51 [95% confidence interval {CI}, 1.07–2.14] in recipients and 2.39 [95% CI, 1.03–5.53] in donors). Among 418 HIV R+ (215 HIV D+/R+, 203 HIV D–/R+), there were 5 KAD cases (incidence, 0.63 cases/100 person-years [95% CI, .26–1.52]): 3 skin-only Kaposi sarcoma (KS), 1 multicentric Castleman disease, and 1 allograft KS. The allograft KS occurred in a female HIV D+/R+ and was likely donor derived. Remaining KAD cases occurred in male HIV D–/R+ and were likely recipient KSHV reactivation or acquisition. Conclusions: In the United States, KSHV seroprevalence in donors and recipients with HIV was high, particularly among MSM. Reassuringly, KSHV-associated disease was rare and primarily attributed to recipient rather than donor-derived KSHV.


  • Benchmarking antimicrobial use to antimicrobial resistance: a comparative study of two hospitals using current National Healthcare Safety Network (NHSN) metrics

    by Carlos A.Q. Santos, Sarah Y. Won, Ryan Dwyer, Caren Perez, William E. Trick, For The Cdc Prevention Epicenters Program

    Objective: We aimed to determine whether benchmarking antimicrobial use (AU) to antimicrobial resistance (AR) using select AU/AR ratios is more informative than AU metrics in isolation.Design: We retrospectively measured AU (antimicrobial therapy days per 1,000 days present) and AU/AR ratios (specific antimicrobial therapy days per corresponding AR event) in two hospitals during 2020 through 2022. We then had antimicrobial stewardship committee members evaluate each AU and corresponding AU/AR value and indicate whether they believed it represented potential overuse, appropriate use, or potential underuse of the antimicrobials, or whether they could not provide an assessment.Setting: Two acute-care hospitals.Patients: Hospitalized patients.Results: In semi-annual facility-wide analyses, echinocandins had a median AU/AR ratio of 658.5 therapy days per fluconazole-resistant Candida event in Hospital A, IV vancomycin had a median AU/AR ratio of 114.9 and 108.2 therapy days per methicillin-resistant Staphylococcus aureus event in Hospital A and B, respectively, and linezolid had a median AU/AR ratio of 33.8 and 88.0 therapy days per vancomycin-resistant Enterococcus event in Hospital A and B, respectively. When AU and AU/AR values were evaluated by stewardship committees, more respondents were able to assess antimicrobial use based on AU/AR values compared to AU values. Based on AU/AR ratios, most respondents identified potential overuse of echinocandins and IV vancomycin in Hospital A, and potential overuse of linezolid and IV vancomycin in Hospital B.Conclusion: Select AU/AR ratios provided informative metrics to antimicrobial stewardship personnel, which can be used to motivate audits of antimicrobial administration to determine appropriateness.